Home › Companies › BIOMARIN PHARMACEUTICAL INC. › 2023-2024
Compiled from SEC Form N-PX filings and BIOMARIN PHARMACEUTICAL INC.’s Form 8-K (Item 5.07 on EDGAR). Page generated 02 October 2026.
Explore BIOMARIN PHARMACEUTICAL INC. in the interactive database Compare manager voting policies
These tallies are BIOMARIN PHARMACEUTICAL INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Elizabeth McKee Anderson | 143,725,729 | -- | -- | 9,003,309 | 10,260,612 | Majority: yes |
| Elect Director: Barbara W. Bodem | 152,126,450 | -- | -- | 602,588 | 10,260,612 | Majority: yes |
| Elect Director: Athena Countouriotis, M.D. | 152,107,502 | -- | -- | 621,536 | 10,260,612 | Majority: yes |
| Elect Director: Willard Dere, M.D. | 147,153,181 | -- | -- | 5,575,857 | 10,260,612 | Majority: yes |
| Elect Director: Mark J. Enyedy | 152,125,947 | -- | -- | 603,091 | 10,260,612 | Majority: yes |
| Elect Director: Alexander Hardy | 151,780,693 | -- | -- | 948,345 | 10,260,612 | Majority: yes |
| Elect Director: Elaine J. Heron, Ph.D. | 144,192,766 | -- | -- | 8,536,272 | 10,260,612 | Majority: yes |
| Elect Director: Maykin Ho, Ph.D. | 143,813,807 | -- | -- | 8,915,231 | 10,260,612 | Majority: yes |
| Elect Director: Robert J. Hombach | 149,094,947 | -- | -- | 3,634,091 | 10,260,612 | Majority: yes |
| Elect Director: Richard A. Meier | 146,622,137 | -- | -- | 6,106,901 | 10,260,612 | Majority: yes |
| Elect Director: David E.I. Pyott, M.D. (Hon.) | 146,332,496 | -- | -- | 6,396,542 | 10,260,612 | Majority: yes |
| Proposal 2: Ratification of the Selection of Independent Registered Public Accounting Firm The ratification of the selection of KPMG LLP as BioMarin's independent registered public accounting firm for the fiscal year ending December 31, 2024, as set forth in t | 156,548,552 | 6,404,458 | 36,640 | -- | -- | Majority: yes |
| Proposal 3: Advisory Vote on the Compensation of Named Executive Officers The advisory (non-binding) vote to approve the compensation of BioMarin's named executive officers, as set forth in the Proxy Statement, received the following votes: | 141,887,490 | 10,757,670 | 83,878 | -- | 10,260,612 | Majority: yes |
Source: BIOMARIN PHARMACEUTICAL INC., Form 8-K — read the filing on EDGAR.
Each item below shows how the 569 asset managers that disclosed a BIOMARIN PHARMACEUTICAL INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of BIOMARIN PHARMACEUTICAL INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 19 wordings of this item as funds reported it.
93% Majority: yes · of votes cast
BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Proposal 3: Advisory Vote on the Compensation of Named Executive Officers The advisory (non-binding) vote to approve the compensation of BioMarin's named executive officers, as set forth in the Proxy Statement, received ”): 141,887,490 for, 10,757,670 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 189,776,577 outstanding shares: 75% for, 6% against (80% of the company cast a for/against vote).
The 565 asset managers below cast 96% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 31,417,782 | 0 | 0 | 0 | For |
| Dodge & Cox | 23,724,864 | 0 | 0 | 0 | For |
| PRIMECAP MANAGEMENT CO/CA/ | 17,933,372 | 0 | 0 | 0 | For |
| BlackRock | 12,848,851 | 387 | 0 | 0 | For |
| State Street | 8,516,927 | 0 | 0 | 0 | For |
| Capital Research Global Investors | 6,517,745 | 0 | 0 | 0 | For |
| VIKING GLOBAL INVESTORS LP | 6,416,288 | 0 | 0 | 0 | For |
| AMCAP FUND | 4,909,896 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 3,611,116 | 0 | 0 | 0 | For |
| Fidelity | 3,566,886 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 3,224,956 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 2,985,409 | 0 | 0 | 0 | For |
| Charles Schwab | 2,791,957 | 0 | 0 | 0 | For |
| JPMorgan | 2,286,741 | 0 | 0 | 0 | For |
| Avoro Capital Advisors LLC | 2,233,162 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,017,115 | 0 | 0 | 0 | For |
| Parnassus | 1,746,002 | 0 | 0 | 0 | For |
| Newton Investment Management North America, LLC | 1,650,301 | 0 | 0 | 0 | For |
| AMERIPRISE FINANCIAL INC | 1,587,644 | 0 | 0 | 0 | For |
| Palo Alto Investors LP | 1,500,749 | 0 | 0 | 0 | For |
| Citadel | 1,464,076 | 0 | 0 | 0 | For |
| American Century | 1,324,826 | 0 | 0 | 0 | For |
| Capital Group | 1,308,894 | 0 | 0 | 0 | For |
| BNY Mellon | 1,215,005 | 86,561 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 1,224,356 | 0 | 0 | 0 | For |
Showing the 25 largest of 565 asset managers. See all 565 in the interactive database.
Combines 5 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Proposal 2: Ratification of the Selection of Independent Registered Public Accounting Firm The ratification of the selection of KPMG LLP as BioMarin's independent registered public accounting firm for the fiscal year end”): 156,548,552 for, 6,404,458 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 189,776,577 outstanding shares: 82% for, 3% against (86% of the company cast a for/against vote).
The 133 asset managers below cast 99.4% of the shares they voted on this item FOR (79,572,737 for, 443,871 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 30,972,914 | 0 | 0 | 0 | For |
| Dodge & Cox | 10,543,625 | 0 | 0 | 0 | For |
| BlackRock | 5,995,495 | 0 | 0 | 0 | For |
| AMCAP FUND | 4,909,896 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 3,611,116 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 3,202,466 | 0 | 0 | 0 | For |
| Fidelity | 3,174,229 | 0 | 0 | 0 | For |
| State Street | 2,447,414 | 144 | 0 | 0 | For |
| Charles Schwab | 1,328,936 | 0 | 0 | 0 | For |
| Capital Group | 1,308,486 | 0 | 0 | 0 | For |
| BNY Mellon | 1,189,693 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 1,173,840 | 0 | 0 | 0 | For |
| Parnassus | 873,001 | 0 | 0 | 0 | For |
| TOUCHSTONE STRATEGIC TRUST | 846,543 | 0 | 0 | 0 | For |
| T. Rowe Price | 835,656 | 0 | 0 | 0 | For |
| TIAA | 760,907 | 0 | 0 | 0 | For |
| American Century | 678,313 | 0 | 0 | 0 | For |
| First Trust | 481,892 | 0 | 0 | 0 | For |
| Dimensional | 469,077 | 0 | 0 | 0 | For |
| JPMorgan | 459,194 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 342,551 | 0 | 0 | Against |
| Goldman Sachs | 303,293 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 294,486 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 259,385 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 183,501 | 0 | 0 | 0 | For |
Showing the 25 largest of 133 asset managers. See all 133 in the interactive database.
Combines 5 wordings of this item as funds reported it.
99.5% Majority: yes · of votes cast
BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Athena Countouriotis, M.D.”): 152,107,502 for, 621,536 withheld, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 189,776,577 outstanding shares: 80% for, 0.4% withheld (80% of the company cast a for/withheld vote).
The 127 asset managers below cast 100% of the shares they voted on this item FOR (79,933,419 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 30,972,914 | 0 | 0 | 0 | For |
| Dodge & Cox | 10,543,625 | 0 | 0 | 0 | For |
| BlackRock | 5,995,495 | 0 | 0 | 0 | For |
| AMCAP FUND | 4,909,896 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 3,611,116 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 3,202,466 | 0 | 0 | 0 | For |
| Fidelity | 3,174,229 | 0 | 0 | 0 | For |
| State Street | 2,447,558 | 0 | 0 | 0 | For |
| Charles Schwab | 1,328,936 | 0 | 0 | 0 | For |
| Capital Group | 1,308,486 | 0 | 0 | 0 | For |
| BNY Mellon | 1,189,693 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 1,173,840 | 0 | 0 | 0 | For |
| Parnassus | 873,001 | 0 | 0 | 0 | For |
| TOUCHSTONE STRATEGIC TRUST | 846,543 | 0 | 0 | 0 | For |
| T. Rowe Price | 835,656 | 0 | 0 | 0 | For |
| TIAA | 760,907 | 0 | 0 | 0 | For |
| American Century | 678,313 | 0 | 0 | 0 | For |
| First Trust | 481,892 | 0 | 0 | 0 | For |
| Dimensional | 469,077 | 0 | 0 | 0 | For |
| JPMorgan | 459,194 | 0 | 0 | 0 | For |
| Aberdeen | 342,551 | 0 | 0 | 0 | For |
| Goldman Sachs | 303,293 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 294,486 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 259,385 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 183,501 | 0 | 0 | 0 | For |
Showing the 25 largest of 127 asset managers. See all 127 in the interactive database.
Combines 5 wordings of this item as funds reported it.
99.3% Majority: yes · of votes cast
BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Alexander Hardy”): 151,780,693 for, 948,345 withheld, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 189,776,577 outstanding shares: 80% for, 0.5% withheld (80% of the company cast a for/withheld vote).
The 127 asset managers below cast 100% of the shares they voted on this item FOR (79,931,049 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 30,972,914 | 0 | 0 | 0 | For |
| Dodge & Cox | 10,543,625 | 0 | 0 | 0 | For |
| BlackRock | 5,995,495 | 0 | 0 | 0 | For |
| AMCAP FUND | 4,909,896 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 3,611,116 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 3,202,466 | 0 | 0 | 0 | For |
| Fidelity | 3,174,229 | 0 | 0 | 0 | For |
| State Street | 2,447,558 | 0 | 0 | 0 | For |
| Charles Schwab | 1,328,936 | 0 | 0 | 0 | For |
| Capital Group | 1,308,486 | 0 | 0 | 0 | For |
| BNY Mellon | 1,189,693 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 1,173,840 | 0 | 0 | 0 | For |
| Parnassus | 873,001 | 0 | 0 | 0 | For |
| TOUCHSTONE STRATEGIC TRUST | 846,543 | 0 | 0 | 0 | For |
| T. Rowe Price | 835,656 | 0 | 0 | 0 | For |
| TIAA | 760,907 | 0 | 0 | 0 | For |
| American Century | 678,313 | 0 | 0 | 0 | For |
| First Trust | 481,892 | 0 | 0 | 0 | For |
| Dimensional | 469,077 | 0 | 0 | 0 | For |
| JPMorgan | 459,194 | 0 | 0 | 0 | For |
| Aberdeen | 342,551 | 0 | 0 | 0 | For |
| Goldman Sachs | 303,293 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 294,486 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 259,385 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 183,501 | 0 | 0 | 0 | For |
Showing the 25 largest of 127 asset managers. See all 127 in the interactive database.
Combines 4 wordings of this item as funds reported it.
99.6% Majority: yes · of votes cast
BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Barbara W. Bodem”): 152,126,450 for, 602,588 withheld, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 189,776,577 outstanding shares: 80% for, 0.4% withheld (80% of the company cast a for/withheld vote).
The 127 asset managers below cast 100% of the shares they voted on this item FOR (79,933,419 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 30,972,914 | 0 | 0 | 0 | For |
| Dodge & Cox | 10,543,625 | 0 | 0 | 0 | For |
| BlackRock | 5,995,495 | 0 | 0 | 0 | For |
| AMCAP FUND | 4,909,896 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 3,611,116 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 3,202,466 | 0 | 0 | 0 | For |
| Fidelity | 3,174,229 | 0 | 0 | 0 | For |
| State Street | 2,447,558 | 0 | 0 | 0 | For |
| Charles Schwab | 1,328,936 | 0 | 0 | 0 | For |
| Capital Group | 1,308,486 | 0 | 0 | 0 | For |
| BNY Mellon | 1,189,693 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 1,173,840 | 0 | 0 | 0 | For |
| Parnassus | 873,001 | 0 | 0 | 0 | For |
| TOUCHSTONE STRATEGIC TRUST | 846,543 | 0 | 0 | 0 | For |
| T. Rowe Price | 835,656 | 0 | 0 | 0 | For |
| TIAA | 760,907 | 0 | 0 | 0 | For |
| American Century | 678,313 | 0 | 0 | 0 | For |
| First Trust | 481,892 | 0 | 0 | 0 | For |
| Dimensional | 469,077 | 0 | 0 | 0 | For |
| JPMorgan | 459,194 | 0 | 0 | 0 | For |
| Aberdeen | 342,551 | 0 | 0 | 0 | For |
| Goldman Sachs | 303,293 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 294,486 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 259,385 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 183,501 | 0 | 0 | 0 | For |
Showing the 25 largest of 127 asset managers. See all 127 in the interactive database.
Combines 5 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: David E.I. Pyott, M.D. (Hon.)”): 146,332,496 for, 6,396,542 withheld, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 189,776,577 outstanding shares: 77% for, 3% withheld (80% of the company cast a for/withheld vote).
The 127 asset managers below cast 100% of the shares they voted on this item FOR (79,905,893 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 30,972,914 | 0 | 0 | 0 | For |
| Dodge & Cox | 10,543,625 | 0 | 0 | 0 | For |
| BlackRock | 5,995,495 | 0 | 0 | 0 | For |
| AMCAP FUND | 4,909,896 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 3,611,116 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 3,202,466 | 0 | 0 | 0 | For |
| Fidelity | 3,174,229 | 0 | 0 | 0 | For |
| State Street | 2,447,327 | 0 | 231 | 0 | For |
| Charles Schwab | 1,328,936 | 0 | 0 | 0 | For |
| Capital Group | 1,308,486 | 0 | 0 | 0 | For |
| BNY Mellon | 1,189,693 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 1,173,840 | 0 | 0 | 0 | For |
| Parnassus | 873,001 | 0 | 0 | 0 | For |
| TOUCHSTONE STRATEGIC TRUST | 846,543 | 0 | 0 | 0 | For |
| T. Rowe Price | 835,656 | 0 | 0 | 0 | For |
| TIAA | 760,907 | 0 | 0 | 0 | For |
| American Century | 678,313 | 0 | 0 | 0 | For |
| First Trust | 481,892 | 0 | 0 | 0 | For |
| Dimensional | 469,077 | 0 | 0 | 0 | For |
| JPMorgan | 459,194 | 0 | 0 | 0 | For |
| Aberdeen | 342,551 | 0 | 0 | 0 | For |
| Goldman Sachs | 303,293 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 294,486 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 259,385 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 183,501 | 0 | 0 | 0 | For |
Showing the 25 largest of 127 asset managers. See all 127 in the interactive database.
Combines 7 wordings of this item as funds reported it.
94% Majority: yes · of votes cast
BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Elizabeth McKee Anderson”): 143,725,729 for, 9,003,309 withheld, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 189,776,577 outstanding shares: 76% for, 5% withheld (80% of the company cast a for/withheld vote).
The 127 asset managers below cast 100% of the shares they voted on this item FOR (79,905,893 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 30,972,914 | 0 | 0 | 0 | For |
| Dodge & Cox | 10,543,625 | 0 | 0 | 0 | For |
| BlackRock | 5,995,495 | 0 | 0 | 0 | For |
| AMCAP FUND | 4,909,896 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 3,611,116 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 3,202,466 | 0 | 0 | 0 | For |
| Fidelity | 3,174,229 | 0 | 0 | 0 | For |
| State Street | 2,447,327 | 0 | 231 | 0 | For |
| Charles Schwab | 1,328,936 | 0 | 0 | 0 | For |
| Capital Group | 1,308,486 | 0 | 0 | 0 | For |
| BNY Mellon | 1,189,693 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 1,173,840 | 0 | 0 | 0 | For |
| Parnassus | 873,001 | 0 | 0 | 0 | For |
| TOUCHSTONE STRATEGIC TRUST | 846,543 | 0 | 0 | 0 | For |
| T. Rowe Price | 835,656 | 0 | 0 | 0 | For |
| TIAA | 760,907 | 0 | 0 | 0 | For |
| American Century | 678,313 | 0 | 0 | 0 | For |
| First Trust | 481,892 | 0 | 0 | 0 | For |
| Dimensional | 469,077 | 0 | 0 | 0 | For |
| JPMorgan | 459,194 | 0 | 0 | 0 | For |
| Aberdeen | 342,551 | 0 | 0 | 0 | For |
| Goldman Sachs | 303,293 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 294,486 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 259,385 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 183,501 | 0 | 0 | 0 | For |
Showing the 25 largest of 127 asset managers. See all 127 in the interactive database.
Combines 5 wordings of this item as funds reported it.
94% Majority: yes · of votes cast
BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Elaine J. Heron, Ph.D.”): 144,192,766 for, 8,536,272 withheld, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 189,776,577 outstanding shares: 76% for, 4% withheld (80% of the company cast a for/withheld vote).
The 127 asset managers below cast 100% of the shares they voted on this item FOR (78,663,460 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 30,972,914 | 0 | 0 | 0 | For |
| Dodge & Cox | 10,543,625 | 0 | 0 | 0 | For |
| BlackRock | 5,995,495 | 0 | 0 | 0 | For |
| AMCAP FUND | 4,909,896 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 3,611,116 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 3,202,466 | 0 | 0 | 0 | For |
| Fidelity | 3,174,229 | 0 | 0 | 0 | For |
| State Street | 2,447,184 | 0 | 374 | 0 | For |
| Charles Schwab | 1,328,936 | 0 | 0 | 0 | For |
| Capital Group | 1,308,486 | 0 | 0 | 0 | For |
| BNY Mellon | 1,189,693 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 1,173,840 | 0 | 0 | 0 | For |
| Parnassus | 0 | 0 | 873,001 | 0 | Abstain |
| TOUCHSTONE STRATEGIC TRUST | 846,543 | 0 | 0 | 0 | For |
| T. Rowe Price | 835,656 | 0 | 0 | 0 | For |
| TIAA | 760,907 | 0 | 0 | 0 | For |
| American Century | 678,313 | 0 | 0 | 0 | For |
| First Trust | 481,892 | 0 | 0 | 0 | For |
| Dimensional | 469,077 | 0 | 0 | 0 | For |
| JPMorgan | 459,194 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 0 | 342,551 | 0 | Abstain |
| Goldman Sachs | 303,293 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 294,486 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 259,385 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 183,501 | 0 | 0 | 0 | For |
Showing the 25 largest of 127 asset managers. See all 127 in the interactive database.
Combines 5 wordings of this item as funds reported it.
99.6% Majority: yes · of votes cast
BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Mark J. Enyedy”): 152,125,947 for, 603,091 withheld, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 189,776,577 outstanding shares: 80% for, 0.4% withheld (80% of the company cast a for/withheld vote).
The 127 asset managers below cast 100% of the shares they voted on this item FOR (79,933,419 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 30,972,914 | 0 | 0 | 0 | For |
| Dodge & Cox | 10,543,625 | 0 | 0 | 0 | For |
| BlackRock | 5,995,495 | 0 | 0 | 0 | For |
| AMCAP FUND | 4,909,896 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 3,611,116 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 3,202,466 | 0 | 0 | 0 | For |
| Fidelity | 3,174,229 | 0 | 0 | 0 | For |
| State Street | 2,447,558 | 0 | 0 | 0 | For |
| Charles Schwab | 1,328,936 | 0 | 0 | 0 | For |
| Capital Group | 1,308,486 | 0 | 0 | 0 | For |
| BNY Mellon | 1,189,693 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 1,173,840 | 0 | 0 | 0 | For |
| Parnassus | 873,001 | 0 | 0 | 0 | For |
| TOUCHSTONE STRATEGIC TRUST | 846,543 | 0 | 0 | 0 | For |
| T. Rowe Price | 835,656 | 0 | 0 | 0 | For |
| TIAA | 760,907 | 0 | 0 | 0 | For |
| American Century | 678,313 | 0 | 0 | 0 | For |
| First Trust | 481,892 | 0 | 0 | 0 | For |
| Dimensional | 469,077 | 0 | 0 | 0 | For |
| JPMorgan | 459,194 | 0 | 0 | 0 | For |
| Aberdeen | 342,551 | 0 | 0 | 0 | For |
| Goldman Sachs | 303,293 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 294,486 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 259,385 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 183,501 | 0 | 0 | 0 | For |
Showing the 25 largest of 127 asset managers. See all 127 in the interactive database.
Combines 5 wordings of this item as funds reported it.
94% Majority: yes · of votes cast
BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Maykin Ho, Ph.D.”): 143,813,807 for, 8,915,231 withheld, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 189,776,577 outstanding shares: 76% for, 5% withheld (80% of the company cast a for/withheld vote).
The 127 asset managers below cast 100% of the shares they voted on this item FOR (76,789,899 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 30,883,747 | 0 | 89,167 | 0 | For |
| Dodge & Cox | 10,543,625 | 0 | 0 | 0 | For |
| BlackRock | 5,995,495 | 0 | 0 | 0 | For |
| AMCAP FUND | 4,909,896 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 3,611,116 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 3,202,466 | 0 | 0 | 0 | For |
| Fidelity | 3,174,229 | 0 | 0 | 0 | For |
| State Street | 2,447,448 | 0 | 110 | 0 | For |
| Charles Schwab | 0 | 0 | 1,328,936 | 0 | Abstain |
| Capital Group | 1,308,486 | 0 | 0 | 0 | For |
| BNY Mellon | 1,189,693 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 1,173,840 | 0 | 0 | 0 | For |
| Parnassus | 0 | 0 | 873,001 | 0 | Abstain |
| TOUCHSTONE STRATEGIC TRUST | 846,543 | 0 | 0 | 0 | For |
| T. Rowe Price | 835,656 | 0 | 0 | 0 | For |
| TIAA | 760,907 | 0 | 0 | 0 | For |
| American Century | 678,313 | 0 | 0 | 0 | For |
| First Trust | 481,892 | 0 | 0 | 0 | For |
| Dimensional | 469,077 | 0 | 0 | 0 | For |
| JPMorgan | 459,194 | 0 | 0 | 0 | For |
| Aberdeen | 342,551 | 0 | 0 | 0 | For |
| Goldman Sachs | 303,293 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 294,486 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 259,385 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 183,501 | 0 | 0 | 0 | For |
Showing the 25 largest of 127 asset managers. See all 127 in the interactive database.
Combines 5 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Richard A. Meier”): 146,622,137 for, 6,106,901 withheld, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 189,776,577 outstanding shares: 77% for, 3% withheld (80% of the company cast a for/withheld vote).
The 127 asset managers below cast 100% of the shares they voted on this item FOR (79,548,726 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 30,972,914 | 0 | 0 | 0 | For |
| Dodge & Cox | 10,543,625 | 0 | 0 | 0 | For |
| BlackRock | 5,995,495 | 0 | 0 | 0 | For |
| AMCAP FUND | 4,909,896 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 3,611,116 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 3,202,466 | 0 | 0 | 0 | For |
| Fidelity | 3,174,229 | 0 | 0 | 0 | For |
| State Street | 2,447,412 | 0 | 146 | 0 | For |
| Charles Schwab | 1,328,936 | 0 | 0 | 0 | For |
| Capital Group | 1,308,486 | 0 | 0 | 0 | For |
| BNY Mellon | 1,189,693 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 1,173,840 | 0 | 0 | 0 | For |
| Parnassus | 873,001 | 0 | 0 | 0 | For |
| TOUCHSTONE STRATEGIC TRUST | 846,543 | 0 | 0 | 0 | For |
| T. Rowe Price | 835,656 | 0 | 0 | 0 | For |
| TIAA | 760,907 | 0 | 0 | 0 | For |
| American Century | 678,313 | 0 | 0 | 0 | For |
| First Trust | 481,892 | 0 | 0 | 0 | For |
| Dimensional | 469,077 | 0 | 0 | 0 | For |
| JPMorgan | 459,194 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 0 | 342,551 | 0 | Abstain |
| Goldman Sachs | 303,293 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 294,486 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 259,385 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 183,501 | 0 | 0 | 0 | For |
Showing the 25 largest of 127 asset managers. See all 127 in the interactive database.
Combines 5 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Robert J. Hombach”): 149,094,947 for, 3,634,091 withheld, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 189,776,577 outstanding shares: 79% for, 2% withheld (80% of the company cast a for/withheld vote).
The 127 asset managers below cast 100% of the shares they voted on this item FOR (79,925,556 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 30,972,914 | 0 | 0 | 0 | For |
| Dodge & Cox | 10,543,625 | 0 | 0 | 0 | For |
| BlackRock | 5,995,495 | 0 | 0 | 0 | For |
| AMCAP FUND | 4,909,896 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 3,611,116 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 3,202,466 | 0 | 0 | 0 | For |
| Fidelity | 3,174,229 | 0 | 0 | 0 | For |
| State Street | 2,447,448 | 0 | 110 | 0 | For |
| Charles Schwab | 1,328,936 | 0 | 0 | 0 | For |
| Capital Group | 1,308,486 | 0 | 0 | 0 | For |
| BNY Mellon | 1,189,693 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 1,173,840 | 0 | 0 | 0 | For |
| Parnassus | 873,001 | 0 | 0 | 0 | For |
| TOUCHSTONE STRATEGIC TRUST | 846,543 | 0 | 0 | 0 | For |
| T. Rowe Price | 835,656 | 0 | 0 | 0 | For |
| TIAA | 760,907 | 0 | 0 | 0 | For |
| American Century | 678,313 | 0 | 0 | 0 | For |
| First Trust | 481,892 | 0 | 0 | 0 | For |
| Dimensional | 469,077 | 0 | 0 | 0 | For |
| JPMorgan | 459,194 | 0 | 0 | 0 | For |
| Aberdeen | 342,551 | 0 | 0 | 0 | For |
| Goldman Sachs | 303,293 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 294,486 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 259,385 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 183,501 | 0 | 0 | 0 | For |
Showing the 25 largest of 127 asset managers. See all 127 in the interactive database.
Combines 5 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Willard Dere, M.D.”): 147,153,181 for, 5,575,857 withheld, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 189,776,577 outstanding shares: 78% for, 3% withheld (80% of the company cast a for/withheld vote).
The 127 asset managers below cast 100% of the shares they voted on this item FOR (79,040,610 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 30,972,914 | 0 | 0 | 0 | For |
| Dodge & Cox | 10,543,625 | 0 | 0 | 0 | For |
| BlackRock | 5,995,495 | 0 | 0 | 0 | For |
| AMCAP FUND | 4,909,896 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 3,611,116 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 3,202,466 | 0 | 0 | 0 | For |
| Fidelity | 3,174,229 | 0 | 0 | 0 | For |
| State Street | 2,447,327 | 0 | 231 | 0 | For |
| Charles Schwab | 1,328,936 | 0 | 0 | 0 | For |
| Capital Group | 1,308,486 | 0 | 0 | 0 | For |
| BNY Mellon | 1,189,693 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 1,173,840 | 0 | 0 | 0 | For |
| Parnassus | 0 | 0 | 873,001 | 0 | Abstain |
| TOUCHSTONE STRATEGIC TRUST | 846,543 | 0 | 0 | 0 | For |
| T. Rowe Price | 835,656 | 0 | 0 | 0 | For |
| TIAA | 760,907 | 0 | 0 | 0 | For |
| American Century | 678,313 | 0 | 0 | 0 | For |
| First Trust | 481,892 | 0 | 0 | 0 | For |
| Dimensional | 469,077 | 0 | 0 | 0 | For |
| JPMorgan | 459,194 | 0 | 0 | 0 | For |
| Aberdeen | 342,551 | 0 | 0 | 0 | For |
| Goldman Sachs | 303,293 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 294,486 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 259,385 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 183,501 | 0 | 0 | 0 | For |
Showing the 25 largest of 127 asset managers. See all 127 in the interactive database.
Combines 2 wordings of this item as funds reported it.
100% fund support · no official result
The 6 asset managers below cast 100% of the shares they voted on this item FOR (616,999 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| RBB FUND, INC. | 515,284 | 0 | 0 | 0 | For |
| TEALWOOD ASSET MANAGEMENT INC | 84,084 | 0 | 0 | 0 | For |
| TIMOTHY PLAN | 9,892 | 0 | 0 | 0 | For |
| Gabelli | 6,925 | 0 | 0 | 0 | For |
| Zacks Trust | 789 | 0 | 0 | 0 | For |
| Boltwood Capital Management | 25 | 0 | 0 | 0 | For |
Ranked by the number of BIOMARIN PHARMACEUTICAL INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 189,776,577 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 16.56% |
| 2 | Dodge & Cox | 12.50% |
| 3 | PRIMECAP MANAGEMENT CO/CA/ | 9.45% |
| 4 | BlackRock | 6.77% |
| 5 | State Street | 4.49% |
| 6 | Capital Research Global Investors | 3.43% |
| 7 | VIKING GLOBAL INVESTORS LP | 3.38% |
| 8 | AMCAP FUND | 2.59% |
| 9 | PRIMECAP Odyssey Funds | 1.90% |
| 10 | Fidelity | 1.88% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| Vanguard Group | 9.79% | 13F |
| PRIMECAP Management Company | 9.70% | DEF14A |
| BlackRock, Inc. | 7.77% | DEF14A |
| Dodge & Cox | 7.37% | DEF14A |
| S.S. OR | 7.37% | 13G |
| Capital Research Global Investors | 5.68% | DEF14A |
| State Street | 3.63% | 13F |
| Norges Bank | 1.52% | 13F |
| Millennium Management | 1.39% | 13F |
| BNY Mellon | 1.39% | 13F |
Percentages above are of 189,776,577 shares outstanding, as reported by BIOMARIN PHARMACEUTICAL INC. on its Form 10-Q dated 2024-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from BIOMARIN PHARMACEUTICAL INC.’s 10-Q dated 2024-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At BIOMARIN PHARMACEUTICAL INC.'s shareholder meeting held 2024-05-21, in the 2023-2024 proxy season, 569 asset managers reported how they voted in their SEC Form N-PX filings, covering 6,877 separate fund positions. Their filings are grouped here into 14 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as… — FOR was 93% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: BIOMARIN PHARMACEUTICAL INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission (filing date not recorded for this item).
BIOMARIN PHARMACEUTICAL INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.